Prognostic factors in patients with recurrent or metastatic retroperitoneal leiomyosarcoma

Li, Qian; Zhuang, Rongyuan; Zhu, Jun; Lu, Weiqi; Hou, Yayi; Liu, Ju; Zhang, Yong; Wang, Yan; Liu, Tianshu; Wang, Zhiming; Zhou, Yuhong

doi:10.2217/fon.15.54

Cited by 7 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The FNCLCC system is a commonly used histological grading system for STS, and it is one of the best indicators for predicting the metastasis-free survival and OS ( 21 ). This study was similar to a previous study reported by Qian Li et al., for RLMS patients with recurrent or metastatic disease who had a higher FNCLCC grade experienced worse prognosis ( 22 ). Consistent with previous reports on RPS, patients with multifocal lesions accounted for 23% of all subjects in this study; in addition, the mortality risk of patients with multifocal lesion increased by twice compared with non-multifocal lesion ( 23 ).…”

Section: Discussionsupporting

confidence: 92%

Nomogram predicting overall survival after surgical resection for retroperitoneal leiomyosarcoma patients

et al. 2023

Self Cite

View full text Add to dashboard Cite

BackgroundSurgery is the best way to cure the retroperitoneal leiomyosarcoma (RLMS), and there is currently no prediction model on RLMS after surgical resection. The objective of this study was to develop a nomogram to predict the overall survival (OS) of patients with RLMS after surgical resection.MethodsPatients who underwent surgical resection from September 2010 to December 2020 were included. The nomogram was constructed based on the COX regression model, and the discrimination was assessed using the concordance index. The predicted OS and actual OS were evaluated with the assistance of calibration plots.Results118 patients were included. The median OS for all patients was 47.8 (95% confidence interval (CI), 35.9-59.7) months. Most tumor were completely resected (n=106, 89.8%). The proportions of French National Federation of Comprehensive Cancer Centres (FNCLCC) classification were equal as grade 1, grade 2, and grade 3 (31.4%, 30.5%, and 38.1%, respectively). The tumor diameter of 73.7% (n=85) patients was greater than 5 cm, the lesions of 23.7% (n=28) were multifocal, and 55.1% (n=65) patients had more than one organ resected. The OS nomogram was constructed based on the number of resected organs, tumor diameter, FNCLCC grade, and multifocal lesions. The concordance index of the nomogram was 0.779 (95% CI, 0.659-0.898), the predicted OS and actual OS were in good fitness in calibration curves.ConclusionThe nomogram prediction model established in this study is helpful for postoperative consultation and the selection of patients for clinical trial enrollment.

show abstract

Section: Discussionsupporting

confidence: 92%

Nomogram predicting overall survival after surgical resection for retroperitoneal leiomyosarcoma patients

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…The FNCLCC system is a commonly used histological grading system for soft tissue sarcomas, and it is one of the best indicators for predicting metastasis-free survival and OS [15]. This study is similar to the previous study reported by Qian Li et al, for RLMS patients with recurrent or metastatic disease who had a higher FNCLCC grade experienced worse prognosis [16]. Consistent with previous reports on RPS, patients with multifocal disease accounted for 23% of patients in this study [17], and compared with single-center disease, the risk of death in patients with multifocal disease increased by two times.…”

Section: Discussionsupporting

confidence: 89%

Nomogram Predicting Overall Survival After Surgical Resection For Retroperitoneal Leiomyosarcoma Patients

Zhuang

Tong

Fang

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Aim: To develop a survival nomogram for patients with retroperitoneal leiomyosarcoma (RLMS) after surgery.Methods: 118 patients with RLMS after surgical resection at the General Surgery Department, Shanghai Public Health Clinical Center, Fudan University were retrospectively analyzed. The nomogram was constructed based on COX regression model and discrimination was assessed using the concordance index (c-index). The predicted and actual survival was evaluated through calibration plots.Results: The c-index of the nomogram was 0.779 (95% CI, 0.659-0.898). The predicted and actual survival probabilities are in good agreement in all calibration curve.Conclusion: This study built the first survival nomogram for patients with surgical resected RLMS.

show abstract

“…LMS is relatively rare representing 10–20% of soft tissue sarcomas . It can appear at almost all anatomic sites such as the uterus , retroperitoneum , extremities , and blood vessels . Uterine LMS is the most common site‐specific group with an estimated incidence of 0.64 cases per 100,000 women .…”

Section: Introductionmentioning

confidence: 99%

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience

et al. 2016

View full text Add to dashboard Cite

Advanced stage leiomyosarcoma (LMS) is incurable with current systemic antitumor therapies. Therefore, there is clinical interest in exploring novel therapeutic regimens to treat LMS. We reviewed the medical records of 75 consecutive patients with histologically confirmed metastatic LMS, who had been referred to the Clinical Center for Targeted Therapy at MD Anderson Cancer Center. To lay the foundation for potential phase I trials for the treatment of advanced LMS, we analyzed tumor response and survival outcome data. The frequent hotspot gene aberrations that we observed were the TP53 mutation (65%) and RB1 loss/mutation (45%) detected by Sequenom or next‐generation sequencing. Among patients treated with gene aberration‐related phase I trial therapy, the median progression‐free survival was 5.8 months and the median overall survival was 15.9 months, significantly better than in patients without therapy (1.9 months, P = 0.001; and 8.7 months, P = 0.013, respectively). Independent risk factors that predicted shorter overall survival included hemoglobin <10 g/dL, body mass index <30 kg/m2, serum albumin <3.5 g/dL, and neutrophil above upper limit of normal. The median survivals were 19.9, 7.6, and 0.9 months for patients with 0, 1 or 2, and ≥3 of the above risk factors, respectively (P < 0.001). A prognostic scoring system that included four independent risk factors might predict survival in patients with metastatic LMS who were treated in a phase I trial. Gene aberration‐related therapies led to significantly better clinical benefits, supporting that further exploration with novel mechanism‐driven therapeutic regimens is warranted.

show abstract

Prognostic factors in patients with recurrent or metastatic retroperitoneal leiomyosarcoma

Cited by 7 publications

References 27 publications

Nomogram predicting overall survival after surgical resection for retroperitoneal leiomyosarcoma patients

Nomogram predicting overall survival after surgical resection for retroperitoneal leiomyosarcoma patients

Nomogram Predicting Overall Survival After Surgical Resection For Retroperitoneal Leiomyosarcoma Patients

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience

Contact Info

Product

Resources

About